Navigation Links
Ozarelix Phase 2 Data Presented at 29th Congress of the Societe Internationale d'Urologie
Date:9/5/2007

tion on Day1 and Day 15 in one of five dose groups:

Group 1: placebo, + placebo

Group 2: 5mg ozarelix + 5mg ozarelix;

Group 3: 10mg ozarelix +10mg ozarelix;

Group 4: 15mg ozarelix + 15mg ozarelix; and,

Group 5: 20mg ozarelix + placebo.

Study participants were followed for six months. The primary efficacy endpoint was a change in the International Prostate Symposium Score (IPSS) at 12 weeks compared to baseline. Secondary efficacy endpoints included changes in IPSS Quality of Life (QoL), IPSS improvement by > 30% and > 40%, uroflow values (Qmax), PVR and prostate volume at time points up to 28 weeks. Safety analysis included changes in erectile function (IIEF-5), treatment emergent AEs, lab values (including testosterone, PSA) and vital signs. Mean age was 69.1 (range 52 - 85), IPSS 19.8, Qmax 9.7 mL/sec and prostate size (cm cubed) 41.6 at baseline.

Compared to baseline, ozarelix significantly improved scores for IPSS, IPSS > 30% change and Qmax, at 12 and 28 weeks versus placebo. Testosterone levels declined transiently, but returned to baseline in all groups by 6 weeks. No impact on erectile function was observed; IIEF-5 scores remained unchanged from baseline for all treatment groups at all timepoints.

Ozarelix was well tolerated and maintained statistically significant and clinically meaningful efficacy in the treatment of LUTS secondary to BPH for six months following dosing. Serious Adverse Events were reported in 4 patients but were not considered treatment related. No systemic allergic reactions were seen, and the injections were well tolerated.

About Ozarelix and Development Alliance with AEterna Zentaris

Ozarelix is a fourth generation Luteinizing Hormone Releasing Hormone (LHRH) antagonist administered as an intramuscular injection. In August 2004, Spectrum received an exclusive license from AEterna Zentaris to develop and market ozarelix for all potential indications in North America (inclu
'/>"/>

SOURCE Spectrum Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. AEterna Zentaris Partner, Spectrum, Discloses Detailed Phase 2 Data for Ozarelix, in BPH at Annual AUA Meeting
2. Ozarelix Phase 2 Data in Benign Prostatic Hypertrophy Presented at Annual Meeting of American Urological Association
3. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
4. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
11. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... , September 19, 2014 ... IQ den äußerst erfolgreichen Serialisierungs-Countdown-Kalender aktualisiert, der jetzt ... interaktive PDF, verfügbar unter pharmaserialisation.com , zeigt ... sie jeweils in Kraft treten. Für ... nicht länger um das "ob", sondern darum, "wann" ...
(Date:9/19/2014)... VIENNA , Sept. 19, 2014 ... positive interim clinical data for its lead candidate ITCA ... diabetes patients with high baseline HbA1c levels at the ... for the Study of Diabetes (EASD). Data from the ... reduced levels of blood sugar in patients with poorly ...
(Date:9/19/2014)... Mass. , Sept. 19, 2014   Personal ... advanced cancer genome analysis and testing services, and ... and developing highly selective kinase inhibitors for genomically ... study of malignant mixed Mullerian tumors (MMMT), an ... system, also known as carcinosarcoma. The new ...
Breaking Medicine Technology:Pharma IQ stellt weltweite Serialisierungsfristen in seinen Countdown-Kalender 2014 - 2018 2Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 2Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 3Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 4First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 2First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 3First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 4
... 2011 Seal Shield LLC today announced ... for the iPad.  The product has been designed specifically ... use in hospital settings. The Seal Shield ... which is resistant to liquids including blood and bleach. ...
... MALVERN, Pa., Feb. 21, 2011 Today, Siemens (NYSE: ... Overhage, MD, PhD, as Chief Medical Informatics Officer (CMIO), of ... of the In diana Health Information Exchange ... this not-for-profit organization. In his role at Siemens, Marc will ...
Cached Medicine Technology:Siemens Appoints Overhage as New Chief Medical Informatics Officer 2
(Date:9/19/2014)... FRIDAY, Sept. 19, 2014 (HealthDay News) -- U.S. military ... risk of skin cancer, according to a new study. ... serving abroad, researchers revealed. In some cases, military personnel ... in the color, shape or size of their moles ... can be risk factors for skin cancer, the study ...
(Date:9/19/2014)... U.S. Food and Drug Administration approved a new type 2 ... class of once-a-week injectable drugs that help manage blood sugar ... is a new treatment option, which can be used alone ... levels in the overall management of type 2 diabetes," Dr. ... Evaluation II, said in an agency news release. ...
(Date:9/19/2014)... a leading anti-ageing clinic has called its HGH Therapy ... has grown tremendously across USA in the last decade with ... It has far reaching benefits for ageing men and women ... and active lifestyle even beyond their middle age. , ... MetroMD said, “HGH or Human Growth hormones are the building ...
(Date:9/19/2014)... published today in the online journal PLoS Outbreaks ... West Africa by the end of the month if ... State University and Harvard University researchers also discovered through ... significantly increased in August in Liberia and Guinea, around ... place, indicating that the mass quarantine efforts may have ...
(Date:9/19/2014)... September 19, 2014 Famous Vancouver company, ... that it has now become a one-stop-solution for heating, ... businesses in Vancouver. The company has achieved this status ... to its customers. While there are many companies that ... have a single vendor who can offer all of ...
Breaking Medicine News(10 mins):Health News:Some U.S. Troops May Face Greater Skin Cancer Risk 2Health News:FDA Approves Another Weekly Injectable Drug for Type 2 Diabetes 2Health News:MetroMD Announces Better HGH Therapy - the ‘God Particle’ of Human Health 2Health News:Research predicts possible 6,800 new Ebola cases this month 2Health News:Pro Ace Now Provides Heating, Air Conditioning, Plumbing & Electrical Services under One Roof 2
... to try it than highest scorers, study found , ... young males has been linked to a much higher ... their most intelligent counterparts, researchers say. , The analysis, ... doesn,t prove that low intelligence causes suicide. Instead, it ...
... Researchers at Mount Sinai School of Medicine have developed ... in reversing advanced heart failure. SERCA2a (produced as MYDICAR) ... an enzyme that enables the failing heart to pump ... through a routine minimally invasive cardiac catheterization was safe ...
... Geneva 3 June 2010. Following a workshop hosted by ... and physicists today published a strategy for harnessing physics ... long history of application in medicine. Today,s news recognises ... collaboration. The workshop, which was the first of ...
... , ... round of 30 Days of Intentions to mark the mid-point of 2010. , ... Los Angeles, CA (PRWEB) June 3, 2010 -- This ... 2010. The 30 Days of Intentions is a challenge to the internet community to commit to ...
... Theurer Cancer Center at Hackensack University Medical Center announced ... abstracts on treatment and diagnostic progress in many different ... Society of Clinical Oncology (ASCO) in Chicago, IL from ... Cancer Center, we,re dedicated to providing extraordinary cancer care ...
... ... supplements, drugs, and medical conditions that can affect the color and odor of urine. , ... Boston, MA (Vocus) June 4, 2010 -- If ... beets turns urine pink or red—which can be alarming because it looks like blood in the ...
Cached Medicine News:Health News:Low IQ Among Males Raises Suicide Risk 2Health News:New gene therapy proves effective in treating severe heart failure 2Health News:Physicists and medics set out strategy on physics for health 2Health News:Intent.com Launches 30 Days of Intentions and Announces Winners of 2010 Intent Web Awards 2Health News:Leading physicians and researchers at the John Theurer Cancer Center present research at ASCO 2Health News:Leading physicians and researchers at the John Theurer Cancer Center present research at ASCO 3Health News:Color, Odor Changes in Urine Usually -- But Not Always -- Harmless, Reports Harvard Women's Health Watch 2
Inquire...
... are accurate to 1 mm. In vivo results ... patients encapsulation scar tissue. Encapsulation scar tissue can ... therefore actual projection may vary from patient to ... surgeon with a scalpel or surgical scissors. All ...
... IQmarkTM Diagnostic Workstation Software offers a ... that digitally stores many different diagnostic ... Microsofts open-architecture products in mind, our ... integration (using ActiveX controls), networking, central ...
... engineered to set a new standard for ... enter the patient demographics, select auto report ... based system uses the latest in software ... of the IQmark Holter algorithm. Simple, intuitive ...
Medicine Products: